A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
Stopped The SBT101 program for AMN was terminated for business/strategic reasons, and there were no safety concerns
Conditions
- AMN
- AMN Gene Mutation
- X-ALD
Interventions
- GENETIC: SBT101
- PROCEDURE: Imitation Procedure
Sponsor
SwanBio Therapeutics, Inc.